HUTCHMED (China) (HMDCF) Net Cash Flow (2018 - 2021)
HUTCHMED (China)'s (HMDCF) quarterly Net Cash Flow came in at $382.8 million in Q2 2021, up 1601.11% year-over-year from $22.5 million in Q2 2020, and up 245.1% quarter-over-quarter from $110.9 million in Q1 2021.
Analysis
HUTCHMED (China) (HMDCF) Net Cash Flow (2018 - 2021) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Net Cash Flow for 4 consecutive years, with $382.8 million the latest figure, recorded in Q2 2021.
- On a quarterly basis, Net Cash Flow rose 1601.11% year-over-year to $382.8 million in Q2 2021; TTM through Jun 2021 was $479.4 million, a 279.31% increase from a year earlier, with the FY2025 full-year figure at -$86.2 million, up 31.69% from the prior year.
- Net Cash Flow was $382.8 million for Q2 2021 at HUTCHMED (China), up from $110.9 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $382.8 million in Q2 2021 and troughed at -$26.8 million in Q2 2018.
- A 4-year average of $63.6 million and a median of $48.4 million in 2018 frame the typical range for Net Cash Flow.
- Across the five-year window, Net Cash Flow plunged 494.75% in 2020 and jumped 1601.11% in 2021, its largest moves.
- Over 4 years, Net Cash Flow stood at $14.7 million in 2018, then surged by 297.29% to $58.5 million in 2019, then sank by 143.59% to -$25.5 million in 2020, then jumped by 1601.11% to $382.8 million in 2021.
- The last three Net Cash Flow figures came in at $382.8 million (Q2 2021), $110.9 million (Q1 2021), and -$25.5 million (Q2 2020), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.49 Bn | 198.50 Bn | 7.24 Bn | 1.95 Bn |
| 2 | Gilead Sciences | 180.93 Bn | 177.75 Bn | 6.22 Bn | -4.43 Bn |
| 3 | Vertex Pharmaceuticals | 132.39 Bn | 124.53 Bn | 2.84 Bn | 652.90 Mn |
| 4 | Regeneron Pharmaceuticals | 82.17 Bn | 74.18 Bn | 3.93 Bn | -504.30 Mn |
| 5 | Argenx Se | 61.05 Bn | 55.87 Bn | 1.37 Bn | - |
| 6 | Moderna | 55.19 Bn | 50.05 Bn | 52.00 Mn | -183.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.99 Bn | 30.68 Bn | 992.69 Mn | -496,000.00 |
| 8 | Biogen | 31.30 Bn | 30.01 Bn | 1.96 Bn | -2.09 Bn |
| 9 | Roivant Sciences | 29.91 Bn | 29.91 Bn | 1.16 Mn | -170.75 Mn |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 382.83 Mn |
| Mar 31, 2021 | 110.93 Mn |
| Jun 30, 2020 | -25.50 Mn |
| Mar 31, 2020 | 11.10 Mn |
| Dec 31, 2019 | 58.51 Mn |
| Sep 30, 2019 | 82.27 Mn |
| Jun 30, 2019 | -4.29 Mn |
| Mar 31, 2019 | 61.96 Mn |
| Dec 31, 2018 | 14.73 Mn |
| Sep 30, 2018 | 43.56 Mn |
| Jun 30, 2018 | -26.78 Mn |
| Mar 31, 2018 | 53.32 Mn |